JPMorgan Boosts Ionis Stock Rating on Strong Drug Pipeline
JPMorgan analyst upgrades Ionis Pharmaceuticals to Overweight, raising price target to $80 from $49, citing strong drug launches and path to profitability.
/ 4 items
#IONS↓
Ionis' ION582: Breakthrough Therapy for Angelman Syndrome
ION582, a new medicine for Angelman Syndrome, received FDA Breakthrough status! It aims to fix the root cause, showing early promise in improving communication, thinking, and movement for this severe neurological condition.
Ionis's Olezarsen (Tryngolza) Revolutionizes Severe Hypertriglyceridemia Treatment with Unprecedented Results
Ionis's olezarsen (Tryngolza) shows "unprecedented" results for severe hypertriglyceridemia, cutting triglycerides by up to 72% and acute pancreatitis events by 85% in Phase 3 trials—a first! Favorable safety. sNDA planned by year-end.
FDA Breakthrough: New Non-Invasive Biomarker to Revolutionize MASH Drug Development
The FDA accepted non-invasive Liver Stiffness Measurement as a surrogate endpoint for MASH clinical trials, replacing biopsies. This key decision accelerates MASH drug development by enabling safer monitoring, speeding recruitment, and predicting patient outcomes.